The Power of Gamma Delta T Cells

Adicet Bio, Inc. is a biotechnology company developing next-generation engineered immune-cell therapeutics based on gamma-delta T-cells.

Gamma-delta T-cells are a subset of T-cells that have a higher likelihood of eradicating solid tumors. Adicet's cost-effective therapy has the potential to dramatically increase the number of cancer patients benefiting from cell therapy.

Adicet is advancing a pipeline of off-the-shelf gamma-delta T-cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL) to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.


Investing partner / fund: